Parvovirus vectors for cancer gene therapy

Bibliography

• TOOLAN HW, LEDINKO N: Growth andcytopathogenecity of H-viruses in humanand simian cell cultures. Nature (1965) 208:812–813.
   PubMed Web of Science ®Google Scholar
• SIEGL G, BATES RC, BERNS KI et al: Characteristics and taxonomy of parvoviridae. Intervirol. (1987) 23:61–73.
   Web of Science ®Google Scholar
• BERNS KI, BOHENZKY RA: Adeno-associated viruses: an update. Adv. Virus Res. (1987) 32:243–307.
   PubMed Web of Science ®Google Scholar
• COTMORE SF, TATERSALL P: The autonomously replicating parvoviruses of vertebrates. Adv. Virus Res. (1987) 33:91–169.
   PubMed Web of Science ®Google Scholar
• BERNS KI, LABOW MA: Parvovirus gene regulation.' Gen. Virol. (1987) 68:601–614.
   PubMed Web of Science ®Google Scholar
• BROCKSTEDT DG, PODSAKOFF GM, FONG L, KURTZMAN G, MUELLER-RUCHHOLTZ W, ENGLEMAN EG: Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. (1999) 92:67–75.
   PubMed Web of Science ®Google Scholar
• KURTZMAN G, COHEN BJ, FIELD AM, OSEAS R, BLEASE PM, YOUNG NS: Immune response to B19 parvovirus and an antibody defect in persistent viral infection.Clin. Invest. (1989) 84:1114–1123.
   Google Scholar
• SEDLIK C, DRIDI A, DERIAUD E et al.: Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody response.Virol (1999) 73:2739–2744.
   Web of Science ®Google Scholar
• SAMULSKI RJ, BERNS KI, TAN M, MUZYCZKA N: Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Nati Acad. Sri. USA (1982) 79:2077–2081.
   PubMed Web of Science ®Google Scholar
• SAMULSKI RJ, CHANG LS, SHENK T: Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. (1989) 63:3822–3838.
   PubMed Web of Science ®Google Scholar
• MAXWELL IH, TERRELL KL, MAXWELL F: Autonomous parvovirus vectors. Methods (2002) 28:168–181.
   PubMed Web of Science ®Google Scholar
• RUSSELL SJ, BRANDENBURGER A, FLEMMING CL, COLLINS MK, ROMMELAERE J: Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus.Virol. (1992) 66.2821–2828.
   Web of Science ®Google Scholar
• KESTLER J, NEEB B, STRUYF S et al.: cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum. Gene Ther. (1999) 10:1619–1632.
   PubMed Web of Science ®Google Scholar
• ROTH JA, CRISTIANO RJ: Gene therapy for cancer: what have we done and where are we going? Natl. Cancer Inst. (1997) 89:21–39.
   Google Scholar
• WEINBERG RA: Tumor suppressor genes. Science (1991) 254:1138–1147.
   PubMed Web of Science ®Google Scholar
• BISHOP JM: Molecular themes in oncogenesis. Cell (1991) 64:235–248.
   PubMed Web of Science ®Google Scholar
• TEPPER RI, MULE JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene The]: (1994) 5:153–164.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM: Paracrine cytokine adjuvants in cancer immunotherapy.Ann. Rev Immunol (1995) 13:399–415.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM: Immunotherapy of cancer. Ann. NY Acad. Sri. (1991) 886:67–72.
   Google Scholar
• TAGAWA M: Cytokine therapy for cancer. Carr. Pharm. Des. (2000) 6:681–699.
   PubMed Web of Science ®Google Scholar
• TOTING T, STORKUS WJ, LOTZE MT: Gene-based strategies for theimmunotherapy of cancer. Ma Med (1997) 75:478–491.
   Google Scholar
• BOCZKOWSKI D, NAIR SK, SNYDER D, GILBOA E: Dendritic cells pulsed with RNA are potent antigen-presenting cells M vitro and in vivo.Exp. Med. (1996) 184:465–472.
   PubMed Web of Science ®Google Scholar
• NAIR SK, BOCZKOWSKI D, MORSE M, CUMMING RI, LYERLY HK, GILBOA E:Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes M vitro using human dendritic cells transfected with RNA. Nat. Biotechnol (1998) 16:364–369.
   PubMed Web of Science ®Google Scholar
• DE VEERMAN M, HEIRMAN C, VAN MEIRVENNE S et al.: Retrovirallytransduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. Immunol (1999) 162:144–151.
   Google Scholar
• BROSSART P, GOLDRATH AW, BUTZ EA, MARTIN S, BEVAN MJ:Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. I Immunol (1997) 158:3270–3276.
   PubMed Web of Science ®Google Scholar
• TILLMAN BW, DEGRUIJL TD, LUYKX-DE BAKKER SZ et al.: Maturationof dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. Immunol (1999) 162:6378–6383.
   Google Scholar
• TILLMAN BW, HAYES TL,DE GRUIJL TD, DOUGLAS JT,CURIEL DT: Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. (2000) 60:5456–5463.
   PubMed Web of Science ®Google Scholar
• VAN GOOL SW, BARCY S, DEVOS S: CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? Res. Lanham' (1995) 146:183–196.
   Google Scholar
• HWU P, YANNELLI J, KRIEGLER M et al.: Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancers in humans. J. Immunol. (1993) 150:4104–4115.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, MULLIGAN R: Gene transfer as cancer therapy. Adv Inamunol. (1995) 58:417–454.
   PubMed Web of Science ®Google Scholar
• WADHWA PD, ZIELSKE SP, ROTH JC, BALLAS CB, BOWMAN JE,GERSON SL: Cancer gene therapy:scientific basis. Ann. Rev Med. (2002) 53:437–452.
   PubMed Web of Science ®Google Scholar
• REID T, GALANIS E, ABBRUZZESE J et al.: Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther. (2001) 8:1618–1626.
   PubMed Web of Science ®Google Scholar
• HABIB N, SALAMA H, ABD EL et al.: Clinical trial of E1B-deleted adenovirus (d11520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. (2002) 9:254–259.
   PubMed Web of Science ®Google Scholar
• REID T, WARREN R, KIRN D: Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene The]: (2002) 9:979–986.
   PubMed Web of Science ®Google Scholar
• KUBO H, GARDNER TA, WADA Y et al:Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. (2003) 14:227–241.
   PubMed Web of Science ®Google Scholar
• SAVONTAUS MJ, SAUTER BV, HUANG TG, WOO SL: Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. (2002) 9:972–979.
   PubMed Web of Science ®Google Scholar
• SPRECHER-GOLDBERGER S,THIRY L, LEFEBVRE N, DEKE GEL D, DE HALLEUX F: Complement-fixation antibodies to adenovirus associated virus, adenoviruses, cytomegaloviruses and herpes simplex viruses in patients with tumors and in control individuals. Am. I. Epidemiol (1971) 94:351–358.
   PubMed Web of Science ®Google Scholar
• GEORGE-FRIES B, BIEDERLACK S, WOLF J, ZUR HAUSEN H: Analysis of proteins, helper dependence and sero-epidemiology of a new human parvovirus. Virology(1984) 134:64–71.
   PubMed Web of Science ®Google Scholar
• ROMMELAERE J, CORNELIS JJ: Anti-neoplastic activity of parvoviruses." Methods (1991) 33:233–251.
   Google Scholar
• LEGENDRE D, ROMMELAERE J: Terminal regions of the NS-1 protein of the parvovirus minute virus if mice are involved in cytotoxicity and promoter trans inhibition." Viral. (1992) 66:5705–5713.
   PubMed Web of Science ®Google Scholar
• VAN PACHTERBEKE C, TUYNDER M, COSYN JP, LESPAGNARD D, ROMMELAERE J: Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. hat. J. Cancer (1993) 55:672–677.
   PubMed Web of Science ®Google Scholar
• LEGRAND C, ROMMELAERE J, CAILLET-FAUQUET P: MVM(p) NS-2 protein expression is required with NS-1 for maximal cytotoxicity in human transformed cells. Virology (1993) 195:149–155.
   PubMed Web of Science ®Google Scholar
• RAJ K, OGSTON P, BEARD P: Virus-mediated killing of cells that lack p53 activity. Nature (2001) 412:914–917.
   PubMed Web of Science ®Google Scholar
• TOOLAN HW, LEDINKO N: Inhibition by H-1 virus of the incidence of tumors produced by adenovirus 12 in hamsters. Virology(1968) 35:475–478.
   PubMed Web of Science ®Google Scholar
• BERGS VV: Rat virus-mediatedsuppression of leukemia induction by Moloney virus in rats. Cancer Res. (1969) 29:1669–1673.
   PubMed Web of Science ®Google Scholar
• BANTEL-SCHAAL U, ZUR HAUSEN H: Adeno-associated viruses inhibit 5V40-transformed cells. Virology (i988) 164:64–74.
   Google Scholar
• LABOW MA, GRAF LH, BERNS KI: Adeno-associated virus gene expression inhibits cellular transformation by heterologous genes. MM. Cell. Biol. (1987) 7:1320–1325.
   Web of Science ®Google Scholar
• RHODE SL, RICHARD SM: Characterization of the trans-activation-responsive element of the parvovirus H-1 P38 promoter.' Virol. (1987) 61:2807–2815.
   PubMed Web of Science ®Google Scholar
• BRANDENBURGER A, LEGENDRE D, AVALOSSE B, ROMMELAERE J: NS-1 and NS-2 proteins may act synergistically in the cytopathogenecity of parvovirus MVMp. Virology (1990) 174:576–584.
   PubMed Web of Science ®Google Scholar
• ANTONI BA, RABSON AB, MILLER IL,TREMPE PJ, CHEJANOVSKI N, CARETER BJ: Adeno-associated virus rep protein inhibits human immunodeficiency virus type 1 production in human cells. J. Viral. (1990) 65:396–404.
   Google Scholar
• SKIADOPOULOS MH, FAUST EA: Mutational analysis of conserved tyrosines in the NS-1 protein of the parvovirus minute virus of mice. Virology (1993) 194:509–517.
   PubMed Web of Science ®Google Scholar
• VANACKER JM, LAUDET V, ADELMANT G, STEHELIN D, ROMMELAERE J: Interconnection between thyroid hormone signaling pathways and parvovirus cytotoxic functions. " Virol (1993) 67:7668–7672.
   PubMed Web of Science ®Google Scholar
• BRANDENBURGER A, RUSSELL S: A novel packaging system for the generation of helper-free oncolytic MVM vector stocks. Gene Ther. (1996) 3:927–931.
   PubMed Web of Science ®Google Scholar
• EL BAKKOURI K, CELEMENT N, VELU A, BRANDENBURGER A: Amplification of MVM(p) vectors through serial infection of a new packaging cell line. Tumor Targeting (1999) 4:210–217.
   Google Scholar
• CLEMENT N, VELU T,BRANDENBURGER A: Construction and production of oncotropic vectors, derived from MVM(p), that share reduced sequence homology with helper plasmids. Cancer Gene Ther. (2002) 9:762–770.
   PubMed Web of Science ®Google Scholar
• CLEMENT N, AVALOSSE B,EL BAKKOURI K, VELU T, BRANDENBURGER A: Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences. J. Vim]. 75:1284-1293.
   Google Scholar
• HAAG A, MENTEN P, VAN DAMME J, DINSART C, ROMMELAERE J, CORNELIS JJ: Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors: generation of antitumor response in recipient mice. Hum. Gene Ther: (2000) 11:597–609.
   PubMed Web of Science ®Google Scholar
• GEISE NA, RAYKOV Z, DEMARTINO L et al: Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine in immunocompetent mice. Cancer Gene Ther. (2002) 9:432–442.
   PubMed Web of Science ®Google Scholar
• MALERBA M, DAEFFLER L,ROMMELAERE J, IGGO RD: Replicating parvoviruses that target colon cancer cells. J. Vim]. (2003) 77:6683–6691.
   Web of Science ®Google Scholar
• OZAWA K, KURTZMAN G,YOUNG NS: Replication of the B19 parvovirus in human bone marrow cell cultures. Science (1986) 233:883–886.
   PubMed Web of Science ®Google Scholar
• BROWN KE, ANDERSON SM, YOUNG NS: Erythrocyte P antigen: cellular receptor for parvovirus B19. Science (1993) 262:114–117.
   PubMed Web of Science ®Google Scholar
• WEIGEL-KELLY KA, YODER MC, SRIVASTAVA A: Recombinant human parvovirus B19 vectors: Erythrocyte P antigen is necessary but not sufficient for successful transduction of humanhematopoietic cells.Viral. (2001)75:4110–4116.
   PubMed Web of Science ®Google Scholar
• WIEGEL-KELLEY KA, YODER MC, SRIVASTAVA A: a5131 integrin as a cellular co-receptor for human parvovirus B19: requirement of functional activation of 131 integrin for viral entry. Blood (2003) 102(12):3927–3933.
   PubMed Web of Science ®Google Scholar
• WANG X-S, YODER MC, ZHOU SZ, SRIVASTAVA A: Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells. Proc. Nati Acad. St". USA (1995) 92:12416–12420.
   PubMed Web of Science ®Google Scholar
• PONNAZHAGAN S, WEIGEL KA, RAIKWAR SP, MUKHERJEE P, YODER MC, SRIVASTAVA A: Recombinant human B19 vectors: erythroid cell-specific delivery and expression of transduced genes. Viral. (1998) 75:5224–5230.
   Google Scholar
• BLACKLOW NR: Adeno-associated viruses of humans. In: Parvovimses and Human Disease, Pattison JR (Ed.), CRC Press, Boca Raton, FL, USA (1988):165–174.
   Google Scholar
• DE LA MAZA LM, CARTER BJ: Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA. J. Natl. Cancer Inst (1981) 67:1323–1326.
   PubMed Web of Science ®Google Scholar
• CUKOR G, BLACKLOW NR, KIBRICK S, SWAN IC: Effect of adeno-associated virus on cancer expression by herpesvirus-transformed hamster cells. J. Natl. Cancer Inst (1975) 55:957–959.
   PubMed Web of Science ®Google Scholar
• HERMONAT PL, MEYERS C, PARHAM GP, SANTIN AD: Inhibition/ stimulation of bovine papillomavirus by adeno-associated virus is time as well as multiplicity dependent. Virology (1998) 247:240–250.
   PubMed Web of Science ®Google Scholar
• HERMONAT PL: Adeno-associated virusinhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res. (1994) 54:2278–2281.
   PubMed Web of Science ®Google Scholar
• HORER M, VVEGER S, BUTZ K, HOPPE-SEYLER F, GEISEN C, KLEINSCHMIDT JA: Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters. J. Viral. (1995) 69:5485–5496.
   PubMed Web of Science ®Google Scholar
• HERMONAT PL, PLOTT RT, SANTIN AD, PARHAM GP, FLICK JT: Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol Oncol. (1997) 66:487–494.
   PubMed Web of Science ®Google Scholar
• WU FY, WU CY, LIN CH, WU CH: Suppression of tumorigenicity in cervical carcinoma HeLa cells by an episomal form of adeno-associated virus. Int. J. Oncol. (1999) 15:101–106.
   PubMed Web of Science ®Google Scholar
• ZHAN D, SANTIN AD, LIU Y et al.: Binding of the human papillomavirus type 16 p97 promoter by the adeno-associated virus Rep78 major regulatory protein correlates with inhibition. J. Biol. Chem. (1999) 274:31619–31624.
   PubMed Web of Science ®Google Scholar
• STRICKLER HD, VISCIDI R, ESCOFFERY C et al.: Adeno-associated virus and development of cervical neoplasia. J. Med. Viroi (1999) 59:60–65.
   PubMed Web of Science ®Google Scholar
• HERMONAT PL: Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adeno-associated virus Rep78. Cancer Lett. (1994) 81:129–136.
   PubMedGoogle Scholar
• SAUDEN P, VLACH J, BEARD P: Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO (2000) 19:4351–4361.
   PubMed Web of Science ®Google Scholar
• SCHMIDT M, AFIONE S, KOTIN Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. Vim/. (2000) 74:9441–9450.
   Web of Science ®Google Scholar
• FURMAN P, MCGUJIRT P, KELLER P, EYFE J, ELION G: Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology (1980) 102:420–430.
   PubMed Web of Science ®Google Scholar
• SU H, CHANG JC, XU SM, KAN YW: Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene The]: (1996) 7:463–470.
   PubMed Web of Science ®Google Scholar
• SU H, LU R, CHANG JC, KAN JW: Tissue-specific expression of herpes simplexvirus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice. Proc. Nati Acad. Sci. USA (1997) 94:13891–13896.
   PubMed Web of Science ®Google Scholar
• SU H, LU R, DING R, KAN YW: Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in a non-ganciclovir (GCV)-treated than in GCV-treated animals. Mol. Ther. (2000) 1:509–525.
   PubMed Web of Science ®Google Scholar
• MIZUNO M, YOSHIDA J, COLOSI P, KURTZMAN G: Adeno-associated virus vector containing thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn. J. Cancer Res (1998) 89:76–80.
   PubMedGoogle Scholar
• MAASS G, BOGEDAIN C, SCHEER U et al.: Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for high transduction efficiency into primary epithelial cancer cells. Hum. Gene The]: (1998) 9:1049–1059.
   PubMed Web of Science ®Google Scholar
• QAZILBASH MH, XIAO X, SETH P, COWAN KH, WALSH CE: Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. (1997) 4:675–682.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J, COLE P, ZIMMERMAN S: Tumor behavior in isolated perfused organs:M vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg. (1996) 164:491–502.
   Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N Engl. J. Med. (1971) 285:1182–1186.
   PubMed Web of Science ®Google Scholar
• GASPARINI G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs (1999) 58:17–38.
   PubMed Web of Science ®Google Scholar
• FELDMAN AL, LIBUTTI SK: Progress in antiangiogenic gene therapy of cancer. Cancer (2000) 89:1181–1194.
   PubMed Web of Science ®Google Scholar
• MALONNE H, LANGER I, KISS R, ATASSI G: Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin. Exp. Metastasis (1999) 17:1–14.
   PubMed Web of Science ®Google Scholar
• SAUTER BV, MARTINET O,ZHANG WJ, MANDELI J, WOO SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of 62tumor growth and metastases. Proc. Natl. Acad. Sci. USA (2000) 97:4802–4807.
   PubMed Web of Science ®Google Scholar
• FELDMAN AL, RESTIFO NP,ALEXANDER HR et al.: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res. (2000) 60:1503–1506.
   Google Scholar
• CHEN CT, UN J, LI Q et al.:Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum. Gene The,: (2000) 11:1983–1996.
   Google Scholar
• GOLDMAN CK, KENDALL RL, CABRERA G et al.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA (1998) 95:8795–8800.
   PubMed Web of Science ®Google Scholar
• REGULIER E, PAUL S,MARIGLIANO M et al.: Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther. (2001) 8:45–54.
   Google Scholar
• SCHIMMENTI S, BOESEN J, CLAASSEN EA, VALERIO D, EINERHAND MP: Long-term genetic modification of rhesus monkey hematopoietic cells following transplantation of adenoassociated virus vector-transduced CD34+ cells. Hum. Gene Ther. (1998) 9:2727–2734.
   PubMed Web of Science ®Google Scholar
• KAY MA, MANNO CS, RAGNI MV et al.: Evidence for gene transfer and expression of Factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. (2000) 24:257–261.
   PubMed Web of Science ®Google Scholar
• MAASS G, BOGEDAIN C, SCHEER U et al.: Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. Hum. Gene Tiler: (1998) 9:1049–1059.
   PubMed Web of Science ®Google Scholar
• HASUMI Y, MIZUKAMI H, URABE M et al.: Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 62.2019–2023.
   Google Scholar
• SHI W, TESCHENDORF C,MUZYCZKA N, SIEMAN DW: Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth M vivo. Can. Gene The,: (2002) 9:513–521.
   Google Scholar
• MA HI, LIN SZ, CHIANG YH et al:Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatindelivered by adeno-associated viral (AAV) vector. Gene The]: (2002) 9:2–11.
   PubMed Web of Science ®Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T, REILLY MO: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 390:404–407.
   PubMed Web of Science ®Google Scholar
• VVENDTNER CM, NOLTE A, MANGOLD E et al.: Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene The]: (1997) 4:726–735.
   PubMed Web of Science ®Google Scholar
• ANDERSON R, MACDONALD I, CORBETT T, HACKING G,LOWDELL MW, PRENTICE HG: Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther. (1997) 8:1125–1135.
   PubMed Web of Science ®Google Scholar
• MANNING WC, PALIARD X, ZHOU S et al.: Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. .1. Virol. (1997) 71:7960–7962.
   Google Scholar
• CLARY BM, COVENEY EC,BLAZER DG et al.: Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system. .1. Immunother. (1997) 20:26–37.
   Google Scholar
• VIEWEG J, BOCZKOWSKI D, ROBERSON KM et al.: Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. (1995) 55:2366–2372.
   PubMed Web of Science ®Google Scholar
• CHIORINI JA, VVENDTNER CM, URCELAY E, SAFER B, HALLEK M, KOTIN RM: High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum. Gene The]: (1995) 6:1531–1541.
   Google Scholar
• LIU DW, TSAO YP, KUNG JT et at: Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. I. Vim/ (2000) 74:2888–2894.
   Google Scholar
• JOOSS K, YANG Y, FISHER KJ, WILSON JM: Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.' Viral. (1998) 5:4212–4223.
   Google Scholar
• BROCKSTEDT DG, PODSAKOFF GM, FONG L, KURTZMAN G, MUELLER-RUCHHOLTZ W, ENGLEMAN EG: Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol (1999) 92:67–75.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, CHIRMULE N, GAO GP, WILSON J: CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. " Viro/. (2000) 74:8003–8010.
   PubMed Web of Science ®Google Scholar
• LIU Y, SANTIN AD, MANE M et al: Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J. Interferon Cytokine Res. (2000) 20:21–30.
   PubMed Web of Science ®Google Scholar
• PONNAZHAGAN S, MAHENDRA G, CURIEL DT, SHAW DR: Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. Virol. (2001) 75:9493–9501.
   Web of Science ®Google Scholar
• PONNAZHAGAN S, MUKHERJEE P, WANG X-S et al.: Adeno-associated virus 2-mediated transduction of primary human bone marrow derived CD34+ hematopoietic progenitor cells: donor variation and correlation of expression with cellular differentiation. J. Virol. (1997) 71:8262–8267.
   PubMed Web of Science ®Google Scholar
• KLEIN-BAUERNSCHMITT P, VON KNEBEL DOEBERITZ M, EHRBAR M, GELETNEKY K, KLEINSCHMIDT J: Improved efficacy of chemotherapy by parvovirus-mediated sensitization of human tumor cells. Appl. Tumor Virol. (1996) 32A:1774–1780.
   Google Scholar
• DUVERGER V, SARTORIUS U, KLEIN-BAUERNSCHMITT P, KRAMMER PH, SCHLEHOFER JR: Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Cancer (2002) 97:706–712.
   Google Scholar
• RENDAHL KG, LEFF SE, OTTEN GR et al: Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat. Biotechnol (1999) 16:757–761.
   Web of Science ®Google Scholar
• YE X, RIVERA VM, ZOLTICK P et al.: Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science (1999) 283:88–91.
   PubMed Web of Science ®Google Scholar
• RIVERA VM, YE X, COURAGE NL et, a/.: Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Nati Acad. Sci. USA (1999) 15:8657–8662.
   Google Scholar